BriaCell Therapeutics Corp.(BCTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BCTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BriaCell Therapeutics Corp. (BCTX), a Healthcare sector company. BCTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), BriaCell Therapeutics Corp. reports net income of $-7.2M, free cash flow of $-7.0M. Top institutional holders of BCTX by reported 13-F value include Cable Car Capital,, SABBY MANAGEMENT,, IRIDIAN ASSET MANAGEMENT /CT, based on the most recent SEC filings. BCTX trades on the Nasdaq exchange and files with the SEC under CIK 1610820. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BriaCell Therapeutics Corp. directly from SEC EDGAR.
Net Income
Q3 2026
$-7.2M
Free Cash Flow
Q3 2026
$-7.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-449.1% YoYOperating Income
+18.4% YoYEPS (Diluted)
-42.4% YoYTotal Assets
+268.7% YoYOp. Cash Flow
-16.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-26.3M -449.1% | $-4.8M +76.4% | $-20.3M +24.4% | $-26.8M -94.3% | $-13.8M |
| Operating Income | $-27.2M +18.4% | $-33.3M -43.2% | $-23.3M -52.2% | $-15.3M -119.2% | $-7.0M |
| EPS (Diluted) | $-62.19 -42.4% | $-43.68 -3260.0% | $-1.30 +24.9% | $-1.73 | — |
| Total Assets | $21.6M +268.7% | $5.9M -78.4% | $27.2M -36.2% | $42.6M -26.6% | $58.0M |
| Operating Cash Flow | $-28.2M -16.8% | $-24.1M -1.6% | $-23.7M -90.2% | $-12.5M -61.1% | $-7.8M |
Get alerted when BCTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BriaCell Therapeutics Corp. including:
Top Institutional Holders of BCTX
Cable Car Capital, LP
$908.5K216,821 shSABBY MANAGEMENT, LLC
$309.7K73,915 shIRIDIAN ASSET MANAGEMENT LLC/CT
$272.4K65,000 shEmpery Asset Management, LP
$93.3K666,600 shHEIGHTS CAPITAL MANAGEMENT, INC
$75.6K540,098 shLuminArx Capital Management LP
$62.9K15,000 shUBS Group AG
$48.4K11,541 shSABBY MANAGEMENT, LLC
$28.9K206,753 shMORGAN STANLEY
$12.7K3,021 shNATIONAL BANK OF CANADA /FI/
$2.6K802 sh
| Fund | Value | Shares |
|---|---|---|
| Cable Car Capital, LP | $908.5K | 216,821 |
| SABBY MANAGEMENT, LLC | $309.7K | 73,915 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $272.4K | 65,000 |
| Empery Asset Management, LP | $93.3K | 666,600 |
| HEIGHTS CAPITAL MANAGEMENT, INC | $75.6K | 540,098 |
| LuminArx Capital Management LP | $62.9K | 15,000 |
| UBS Group AG | $48.4K | 11,541 |
| SABBY MANAGEMENT, LLC | $28.9K | 206,753 |
| MORGAN STANLEY | $12.7K | 3,021 |
| NATIONAL BANK OF CANADA /FI/ | $2.6K | 802 |
More Healthcare Companies
View all Healthcare →Put BCTX on your watchlist
Track score changes the day BriaCell Therapeutics Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BCTX a good stock to buy?
13F Pro's AI-powered analysis of BriaCell Therapeutics Corp. (BCTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCTX are available on the BCTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BCTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BriaCell Therapeutics Corp.'s investment landscape.